Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 166 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: DM Clear all
Terminated No phase listed Observational Results available

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer

NCT00873366
View directory record Official record
Conditions
Breast Cancer
Interventions
dextromethorphan hydrobromide, tamoxifen citrate, high performance liquid chromatography, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, fluorescence imaging
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 27, 2026, 8:18 PM EDT
Recruiting Phase 3 Interventional

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786
View directory record Official record
Conditions
Myositis
Interventions
PF-06823859, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
45
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 27, 2026, 8:18 PM EDT
Completed Not applicable Interventional

Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant

NCT00466518
View directory record Official record
Conditions
Kidney Transplant, Type 2 Diabetes
Interventions
Administration of sitagliptin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 27, 2026, 8:18 PM EDT
Terminated Phase 2 Interventional

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

NCT00913393
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
FG-3019, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 27, 2026, 8:18 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)

NCT01876992
View directory record Official record
Conditions
Diabetes, Pre-diabetes, Obesity
Interventions
Metformin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 27, 2026, 8:18 PM EDT
Completed Phase 1Phase 2 Interventional

BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance

NCT02324309
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
BIOD-531, Humalog Mix 75/25, Humulin R U-500
Drug
Lead sponsor
Biodel
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 27, 2026, 8:18 PM EDT
Recruiting Not applicable Interventional

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

NCT06906640
View directory record Official record
Conditions
Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
Interventions
(IRIS-CKD Management Program): Education, (IRIS-CKD Management Program): GDMT
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 8:18 PM EDT
Completed Phase 2 Interventional Results available

Placebo Controlled Trial of Dextromethorphan in Rett Syndrome

NCT01520363
View directory record Official record
Conditions
Rett Syndrome
Interventions
dextromethorphan, placebo
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
1 Year to 10 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 27, 2026, 8:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Type 1 Diabetes Mellitus Effect on Bone Mineral Density

NCT01633684
View directory record Official record
Conditions
Diabetes Mellitus, Osteoporosis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 27, 2026, 8:18 PM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 27, 2026, 8:18 PM EDT
Completed No phase listed Observational

Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging

NCT03052166
View directory record Official record
Conditions
Breast
Interventions
QT Ultrasound scan
Device
Lead sponsor
QT Ultrasound LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
755 participants
Timeline
2017 – 2020
U.S. locations
2
States / cities
Long Beach, California • Novato, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 27, 2026, 8:18 PM EDT
Terminated Phase 2 Interventional

A Pilot Study of Metabolic Effects of Omentectomy

NCT00565799
View directory record Official record
Conditions
Patients Who Consented to Undergo Laparoscopic Gastric Banding Surgery for Weight Loss and Consent to Participate in This studyBMI ≥35 kg/m2, Confirmed Type 2 Diabetes Treated With Oral Agents and/or Only Diet Therapy, Age 18-64 Years
Interventions
Omentectomy, No intervention
Procedure · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 27, 2026, 8:18 PM EDT
Recruiting Not applicable Interventional

Integrating New Skills Into Diabetes Education With CGM

NCT07463209
View directory record Official record
Conditions
Insulin Dependent Diabetes, Diabetes (DM), Diabetes (Insulin-requiring, Type 1 or Type 2), Diabetes Education, Diabetes Care, Type 1 Diabetes (T1D), Type 2 Diabetes Mellitus (T2DM)
Interventions
Three-stage CGM integration program, One-time clinic-based CGM training, Self-directed CGM training
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 8:18 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

NCT04044690
View directory record Official record
Conditions
Dermatomyositis
Interventions
human immunoglobulin G, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
15
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 27, 2026, 8:18 PM EDT
Completed No phase listed Observational

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

NCT04509193
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Warfarin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
116,049 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 27, 2026, 8:18 PM EDT
Not listed No phase listed Observational

DM DEVICE DISRUPTION SURVEY

NCT05050019
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 27, 2026, 8:18 PM EDT
Completed Not applicable Interventional

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3

NCT00742521
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
glucose clamp
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 27, 2026, 8:18 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex

NCT05062070
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
TolaSure Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 27, 2026, 8:18 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

NCT04999020
View directory record Official record
Conditions
Dermatomyositis
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Irvine, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 27, 2026, 8:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Temperature Perception and Prosthetic Thermoregulation

NCT07215442
View directory record Official record
Conditions
Lower Limb Amputation Below Knee, Diabetes (DM), Skin Temperature Change, Vascular Reactivity
Interventions
Warming stimulus starting at 30 C initial temperature, Warming stimulus starting at 32 C initial temperature, Warming stimulus starting at 34 C initial temperature, Warming stimulus starting at 35 C initial temperature, Cooling stimulus starting at 30 C initial temperature, Cooling stimulus starting at 32 C initial temperature, Cooling stimulus starting at 34 C initial temperature, Cooling stimulus starting at 35 C initial temperature
Other
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 27, 2026, 8:18 PM EDT
Recruiting Not applicable Interventional

Improving Diabetes Care With Strategies For Addressing Health-Related Social Needs and Community Partnerships

NCT07043426
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
THRIVE-DM, Standard of care
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 27, 2026, 8:18 PM EDT
Completed Phase 2 Interventional Results available

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

NCT01905150
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
G-FLIP, G-FLIP-DM, Vitamin C
Drug · Dietary Supplement
Lead sponsor
Bruckner Oncology
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 27, 2026, 8:18 PM EDT
Completed No phase listed Observational

Yield and Safety of Colonoscopy in Patients Older Than 80 Years

NCT00590434
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Not listed
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 27, 2026, 8:18 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

NCT03896945
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 8:18 PM EDT